A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy.

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2011

At a glance

  • Drugs BI 54903 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2011 Actual initiation date Nov 2011 added as reported by ClinicalTrials.gov.
    • 22 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top